DiaMedica Therapeutics Inc. (DMAC) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, DiaMedica Therapeutics reported revenue of $0. Net income was -$32.8M. Operating activities generated -$29.1M of cash, leaving -$29.1M of free cash flow. At fiscal year end, DiaMedica Therapeutics held $61.4M in total assets against $5.3M in total liabilities, including $15.6M of cash and equivalents.
Open the full interactive DiaMedica Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
DiaMedica Therapeutics Key Stats
| Share Price | $7.82 |
|---|---|
| Market Cap | $421.5M |
| 52-Week Range | $5.33 – $9.39 |
| Shares Outstanding | 53.9 million (basic, 2026 Q2) |
DiaMedica Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$12.7M | -$13.6M | -$14.0M | -$21.3M | -$26.7M | -$34.4M |
| Pre-Tax Income | -$12.3M | -$13.6M | -$13.6M | -$19.3M | -$24.4M | -$32.7M |
| Income Tax | $27,000 | $28,000 | $28,000 | $43,000 | $30,000 | $28,000 |
| Net Income | -$12.3M | -$13.6M | -$13.7M | -$19.4M | -$24.4M | -$32.8M |
| Diluted EPS | -$0.78 | -$0.65 | — | — | — | — |
DiaMedica Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$8.6M | -$8.7M | -$10.0M | -$10.1M |
DiaMedica Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.4M | $4.7M | $4.7M | $4.5M | $3.0M | $15.6M |
| Current Assets | $27.9M | $45.4M | $33.8M | $53.7M | $44.6M | $60.6M |
| Total Assets | $28.1M | $45.6M | $34.4M | $54.2M | $46.3M | $61.4M |
| Current Liabilities | $2.0M | $1.5M | $2.2M | $2.8M | $5.4M | $5.1M |
| Total Liabilities | $2.1M | $1.6M | $2.6M | $3.1M | $5.6M | $5.3M |
| Shareholders' Equity | $26.0M | $44.0M | $31.8M | $51.1M | $40.7M | $56.1M |
DiaMedica Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$9.2M | -$12.3M | -$11.5M | -$18.7M | -$22.1M | -$29.1M |
| Cash From Investing | -$16.1M | -$20.5M | $11.5M | -$18.3M | $8.6M | -$2.2M |
| Cash From Financing | $28.8M | $30.1M | -$6,000 | $36.8M | $12.0M | $43.9M |
| Free Cash Flow | -$9.2M | -$12.3M | -$11.6M | -$18.7M | -$22.1M | -$29.1M |
Figures from DiaMedica Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full DiaMedica Therapeutics financials page for every line item.
DiaMedica Therapeutics Company Profile
| Ticker | DMAC |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Minneapolis, Minnesota |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001401040 |
Frequently Asked Questions
What was DiaMedica Therapeutics' revenue in fiscal 2025?
DiaMedica Therapeutics (DMAC) reported revenue of $0 for fiscal 2025.
What is DiaMedica Therapeutics' annual revenue history?
DiaMedica Therapeutics' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was DiaMedica Therapeutics' net income in fiscal 2025?
DiaMedica Therapeutics reported net income of -$32.8M for fiscal 2025.
How much free cash flow did DiaMedica Therapeutics generate in fiscal 2025?
DiaMedica Therapeutics generated -$29.1M of free cash flow in fiscal 2025.
What was DiaMedica Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), DiaMedica Therapeutics reported revenue of $0.
How many shares of DiaMedica Therapeutics are outstanding?
DiaMedica Therapeutics reported a weighted average of 53.9 million basic shares outstanding in 2026 Q2.
What is DiaMedica Therapeutics' market cap?
Based on its latest closing price, DiaMedica Therapeutics (DMAC) has a market capitalization of about $421.5M.
When does DiaMedica Therapeutics' fiscal year end?
DiaMedica Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is DiaMedica Therapeutics headquartered?
DiaMedica Therapeutics lists its business address in Minneapolis, Minnesota in its SEC filings.